title: [Thrombolysis in acute cerebral ischemia].
abstract: During the last years some medical centers have performed emergency treatment for intracranial thromboembolic occlusions by thrombolysis using streptokinase, urokinase, and recombinant tissue plasminogen activator intraarterially or intravenously. So far, it appears that the risk of intracranial hemorrhage with clinical deterioration is not increased by thrombolysis if thrombolysis is performed during the first 8 hours after symptom onset. Successful recanalization of occlusions in the anterior or posterior circulation is associated with a decrease of mortality and morbidity. Intraarterial application of the thrombolytic agent seems to be more effective than intravenous application. However, there is still a lack of controlled studies that could exclusively prove which thrombolytic agent and which mode of application is the most effective with regard to arterial recanalization and clinical outcome.
authors.forename: R
authors.initials: R
authors.lastname: von Kummer
authors.forename: M
authors.initials: M
authors.lastname: Forsting
authors.forename: B
authors.initials: B
authors.lastname: Wildemann
authors.forename: K
authors.initials: K
authors.lastname: Sartor
mesh_terms: D000208:Acute Disease; D002545:Brain Ischemia / Q000188:drug therapy*; D006801:Humans; D013300:Streptokinase / Q000627:therapeutic use*; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*
chemical_list: D013300:Streptokinase; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator
vernacular_title: Thrombolyse bei akuter zerebraler Ischämie.